Focused On-demand Library for tRNA-splicing endonuclease subunit Sen2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q8NCE0

UPID:
SEN2_HUMAN

ALTERNATIVE NAMES:
tRNA-intron endonuclease Sen2

ALTERNATIVE UPACC:
Q8NCE0; B7Z6K1; C9IZI7; G5E9Q3; Q8WTW7; Q9BPU7

BACKGROUND:
tRNA-splicing endonuclease subunit Sen2 constitutes a key component of the RNA processing machinery, responsible for the identification and removal of introns from precursor tRNA molecules. This action is crucial for the generation of functional tRNA, indispensable for protein synthesis. The enzyme's specificity and efficiency underscore its significance in the cellular lifecycle, ensuring the smooth operation of protein production processes.

THERAPEUTIC SIGNIFICANCE:
The association of tRNA-splicing endonuclease subunit Sen2 with Pontocerebellar hypoplasia 2B underscores the protein's therapeutic significance. By elucidating the mechanisms by which mutations in the Sen2 gene contribute to disease pathology, researchers can pave the way for the development of innovative therapeutic interventions. Understanding the role of tRNA-splicing endonuclease subunit Sen2 could open doors to potential therapeutic strategies, offering hope for patients and families affected by this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.